Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiotheranostic Agents in Hematological Malignancies.
Caers J, Duray E, Vrancken L, Marcion G, Bocuzzi V, De Veirman K, Krasniqi A, Lejeune M, Withofs N, Devoogdt N, Dumoulin M, Karlström AE, D'Huyvetter M. Caers J, et al. Among authors: de veirman k. Front Immunol. 2022 Jul 5;13:911080. doi: 10.3389/fimmu.2022.911080. eCollection 2022. Front Immunol. 2022. PMID: 35865548 Free PMC article. Review.
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.
De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA. De Veirman K, et al. Among authors: de bruyne e. Front Oncol. 2014 Dec 8;4:349. doi: 10.3389/fonc.2014.00349. eCollection 2014. Front Oncol. 2014. PMID: 25538893 Free PMC article. Review.
The antigen-binding moiety in the driver's seat of CARs.
Hanssens H, Meeus F, De Veirman K, Breckpot K, Devoogdt N. Hanssens H, et al. Among authors: de veirman k. Med Res Rev. 2022 Jan;42(1):306-342. doi: 10.1002/med.21818. Epub 2021 May 24. Med Res Rev. 2022. PMID: 34028069 Free PMC article. Review.
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy.
Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, De Veirman K, Vanderkerken K, Lahoutte T, Morgenstern A, Bruchertseifer F, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Among authors: de veirman k. Mol Cancer Ther. 2022 Jan;21(1):159-169. doi: 10.1158/1535-7163.MCT-21-0220. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667109 Free PMC article.
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma.
De Veirman K, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E, Hose D, Goyvaert C, Vlummens P, Muyldermans S, Breckpot K, Bruchertseifer F, Morgenstern A, D'Huyvetter M, Devoogdt N. De Veirman K, et al. Oncoimmunology. 2021 Nov 9;10(1):2000699. doi: 10.1080/2162402X.2021.2000699. eCollection 2021. Oncoimmunology. 2021. PMID: 34777918 Free PMC article.
Emerging applications of nanobodies in cancer therapy.
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, Mateusiak L, Zeven K, Valenta H, De Groof TWM, De Vlaeminck Y, Krasniqi A, De Veirman K, Goyvaerts C, D'Huyvetter M, Hernot S, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: de groof twm, de veirman k, de vlaeminck y. Int Rev Cell Mol Biol. 2022;369:143-199. doi: 10.1016/bs.ircmb.2022.03.010. Epub 2022 May 18. Int Rev Cell Mol Biol. 2022. PMID: 35777863
55 results